- Trials with a EudraCT protocol (8)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
8 result(s) found for: Haematological disorders NEC.
Displaying page 1 of 1.
| EudraCT Number: 2016-003226-16 | Sponsor Protocol Number: BP-404 | Start Date*: 2017-02-03 | |||||||||||
| Sponsor Name:Bellicum Pharmaceuticals, Inc. | |||||||||||||
| Full Title: Follow-up of phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders | |||||||||||||
| Medical condition: Hematological disorders (ALL;AML;Non-Hodgkin lymphoma;Myelodysplastic syndromes;Congenital immune deficiencies;Severe aplastic anemia;Fanconi anemia; Osteopetrosis;Selected cases of hemoglobinopath... | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2015-005176-17 | Sponsor Protocol Number: BP-I-008 | Start Date*: 2016-10-20 | |||||||||||
| Sponsor Name:Bellicum Pharmaceuticals, Inc. | |||||||||||||
| Full Title: A Phase I Study of Safety, Pharmacokinetics and Efficacy of Donor BPX-501 Cells and AP1903 Infusion for Children with Recurrent or Minimal Residual Disease Hematologic Malignancies After Allogeneic... | |||||||||||||
| Medical condition: recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-003368-21 | Sponsor Protocol Number: RC 03/08 | Start Date*: 2008-06-04 | ||||||||||||||||
| Sponsor Name:ISTITUTO PER L`INFANZIA BURLO GAROFOLO | ||||||||||||||||||
| Full Title: Pilot trial of CTLA4-Ig (Abatacept) in a child affected by a severe congenital autoimmune syndrome (IPEX) | ||||||||||||||||||
| Medical condition: For patients with a stabilized clinical condition, not recovered in care units for acute problems. | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18 | Gender: Male | |||||||||||||||||
| Trial protocol: IT (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2014-000584-41 | Sponsor Protocol Number: BP-004 | Start Date*: 2014-10-23 | |||||||||||
| Sponsor Name:Bellicum Pharmaceuticals, Inc. | |||||||||||||
| Full Title: Phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ+ T cells in pediatric patients affected by hematological disorders | |||||||||||||
| Medical condition: Hematological disorders (ALL;AML;Non-Hodgkin lymphoma;Myelodysplastic syndromes;Congenital immune deficiencies;Severe aplastic anemia;Fanconi anemia; Osteopetrosis;Selected cases of hemoglobinopath... | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-000376-41 | Sponsor Protocol Number: VORIGENIPHARM | Start Date*: 2019-06-18 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Fundación de Investigación del Hospital Universitario La Paz (FIBHULP) | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: Randomized and multicenter clinical trial to evaluate the effectiveness and efficiency of a voriconazole preemptive genotyping strategy in patients with risk of aspergillosis. | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Invasive fungal disease in the hematologic patient. | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2017-002088-16 | Sponsor Protocol Number: CD19-CAR01 | Start Date*: 2017-12-22 | |||||||||||
| Sponsor Name:Bambino Gesù Children's Hospital | |||||||||||||
| Full Title: Phase I/II study of anti-CD19 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma | |||||||||||||
| Medical condition: Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma | |||||||||||||
|
|||||||||||||
| Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-004058-28 | Sponsor Protocol Number: HN017/HBV-003 | Start Date*: 2006-02-02 |
| Sponsor Name:Henogen | ||
| Full Title: A phase III multicentric, multinational, controlled, randomised, open study comparing the immunogenicity, reactogenicity and safety of Henogen’s new adjuvanted hepatitis B vaccine, HB-AS02V, to th... | ||
| Medical condition: Female and male pre-dialysis, peritoneal dialysis and haemodialysis patients with documented evidence of nonresponse to previous hepatitis B vaccination [non-response to previous hepatitis B vaccin... | ||
| Disease: | ||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
| Trial protocol: HU (Completed) CZ (Completed) BE (Completed) PL (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-000575-14 | Sponsor Protocol Number: SMO032/10/03 | Start Date*: 2012-05-09 | |||||||||||
| Sponsor Name:D&A PHARMA | |||||||||||||
| Full Title: Randomized, multicenter, double-blind, placebo-controlled study of the safety and efficacy of 4 dose regimens of SMO.IR, an oral solid formulation of sodium oxybate, in the maintenance of alcohol a... | |||||||||||||
| Medical condition: maintenance of alcohol abstinence in recently abstinent alcohol-dependent patients | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) CZ (Completed) AT (Completed) IT (Completed) SK (Completed) DE (Completed) ES (Completed) PL (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.